雷氏品牌怎么样 申请店铺

我要投票 雷氏在珍珠粉行业中的票数:910 更新时间:2026-01-10
雷氏是哪个国家的品牌?「雷氏」是 上海雷允上药业有限公司 旗下著名品牌。该品牌发源于上海,由创始人苏俊英在1998-11-13期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力雷氏品牌出海!将品牌入驻外推网,定制雷氏品牌推广信息,可以显著提高雷氏产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

雷氏怎么样

百年老字号雷允上药店始建于苏州,发迹于上海,迄今已有近三百年历史。公元1734年(清雍正十二年)创始于苏州;1860年(清咸丰十年)设“申号”于上海新北门外,1934年设“北号”于河南北路天后宫桥(今河南路桥)北堍,1937年又设北号支店于静安寺路(今南京西路)。由于药店规模较大,资产雄厚,影响面广,早年就被国药同业公认为上海中药店“四大户"之一。中国改革开放以来,经资产重组,工商联手,今日上海雷允上药业雄风再现,成为中国中药行业的强者。雷允上药业历史渊源>>

上海雷允上药业有限公司是上药集团上海市药材有限公司为投资主体成立的集农工商、科工贸、产学研于一体的大型中药企业,历年被认定为上海市高新技术企业、上海市文明单位,是上海市第一批知识产权示范企业,旗下“雷氏”品牌被认定为中国驰名商标,并以20.8亿的品牌价值荣获中国500最具价值品牌称号。近年来,公司及其品牌先后获得中国百年中药老字号企业、最具价值的上海老商标、上海市出口名牌、上海市装备制造业与高新技术产业自主创新品牌、上海现代服务业百强等荣誉称号。

公司拥有严格的质量保证体系。从中药产业链源头GAP规范标准入手,严格原药材采购控制。拥有国家GMP规范要求的中药产业化制造基地,能生产20多个剂型500多个品种。拥有包括中药材、中成药、保健品和名贵参茸等在内的强大的专业营销网络,辐射全国,足迹遍及东南亚、北美、欧洲等地。雷允上连锁多年被评为最具影响力特许品牌。六神丸、雷氏珍菊降压片、雷氏炮天红酒等产品历年被评为上海市名牌产品,在海内外均享有较高的声誉。多年坚持开展社区健康服务,2006年赢得了“全国卫生进社区——相约健康社区行”社会公益奖。

公司传承“至诚至信,关爱生命”的企业追求,竭尽所能地致力于服务社会、造福人类的伟大事业,为弘扬祖国优秀中医药文化,为人类的健康贡献力量。

The century old drugstore under leiyunshang pharmaceutical was founded in Suzhou and started in Shanghai. It has a history of nearly 300 years. It was founded in Suzhou in 1734 (the 12th year of Yongzheng reign in the Qing Dynasty); in 1860 (the 10th year of Xianfeng reign in the Qing Dynasty), it was set up outside the new North Gate of Shanghai; in 1934, it was set up in the north end of hougongqiao (now Henan Road bridge), North Henan Road; in 1937, it was set up in Jingansi Road (now Nanjing West Road). Due to the large scale, strong assets and wide influence of drugstores, they have been recognized as one of the "four big families" of Shanghai Traditional Chinese medicine stores by the pharmaceutical industry in the early years. Since China's reform and opening up, through asset restructuring and joint efforts of industry and commerce, the pharmaceutical industry of Shanghai leiyunshang Pharmaceutical Co., Ltd. has reappeared today, becoming a strong player in the Chinese traditional medicine industry. The history of pharmaceutical industry under leiyunshang pharmaceutical & gt; & gt; Shanghai leiyunshang Pharmaceutical Co., Ltd. is a large-scale traditional Chinese medicine enterprise established by Shanghai Pharmaceutical Group Co., Ltd. as the main investor, integrating agriculture, industry and commerce, science, industry and trade, production, learning and research. It has been recognized as a high-tech enterprise in Shanghai and a civilized unit in Shanghai. It is the first batch of intellectual property demonstration enterprises in Shanghai. Its "Leishi" brand is recognized as a well-known trademark in China Won the title of China's 500 most valuable brand with a brand value of 2.08 billion. In recent years, the company and its brand have successively won the honorary titles of China's century old brand enterprise of traditional Chinese medicine, the most valuable old trademark of Shanghai, Shanghai Export famous brand, independent innovation brand of Shanghai equipment manufacturing industry and high-tech industry, and top 100 modern service industry of Shanghai. The company has a strict quality assurance system. Starting from the gap standard of the source of traditional Chinese medicine industry chain, strictly control the purchase of original Chinese medicine. It has the industrialization manufacturing base of traditional Chinese medicine required by the national GMP standard, and can produce more than 20 dosage forms and more than 500 varieties. It has a strong professional marketing network including traditional Chinese medicine, Chinese patent medicine, health care products and rare ginseng antler, covering the whole country, covering Southeast Asia, North America, Europe and other places. Leiyunshang chain has been rated as the most influential franchise brand for many years. Liushenwan, Zhenju hypotensive tablet and Baotian red wine have been rated as famous brand products in Shanghai over the years, enjoying a high reputation at home and abroad. In 2006, it won the social public welfare award of "national health into the community - meeting healthy communities". The company inherits the enterprise pursuit of "sincere and trustworthy, caring for life", devotes itself to the great cause of serving the society and benefiting the human as much as possible, promotes the excellent traditional Chinese medicine culture of the motherland and contributes to the health of human beings.

本文链接: https://brand.waitui.com/942bfee42.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

马斯克透露特斯拉有大约15万员工,持H-1B签证者不到3000人

一位网友分享美国科技公司雇佣持H-1B签证员工数量的图表,显示特斯拉(445.01, 9.21, 2.11%)雇佣着2908名此类员工,并敦促马斯克在特斯拉裁减持H-1B签证员工的数量。马斯克回应称:“我们这样做绝不是为了省钱。而是为了聘请那些具备专业技能的杰出人才加入我们的团队,而且是以高成本。此外,我们有15万名员工,所以这只是百分之几。”(新浪财经)

35分钟前

雷军:特斯拉确实强,但并非不可战胜

36氪获悉,1月10日,雷军发文称:“看了易车网销量排行榜:特斯拉确实强,但并非不可战胜!我自豪的是,SU7是迄今为止唯一击败Model 3 的同档纯电轿车!出色的产品力和品质,才会有这样的销量。小米YU7,上市仅6个月时间,销量和Model Y 有差距。我相信,假以时日,YU7 也能一较高下!”

35分钟前

外资开年频频加仓中国资产

据上证报,2026年伊始,外资机构对中国资产的配置热情持续升温。记者在港交所披露易检索发现,自2026年1月1日以来,摩根大通在港股密集增持宁德时代、赣锋锂业、信达生物等H股公司,涵盖新能源、生物医药、通信服务等多个领域。“这种现象反映出国际资本对中国经济企稳回升的预期增强,以及港股估值洼地的吸引力凸显,预计2026年内外资机构频频增持的趋势将持续。”一位投行人士对记者表示。此外,2026年以来,景顺中国科技ETF、锐联中国科技创新ETF等多只在美国上市的中国科技类ETF持续吸引资金流入。多家外资巨头认为,中国科技产业长期成长逻辑稳固,中国科技股行情有望在2026年延续。

35分钟前

我国科学家创出全新计算架构提升算力

“傅里叶变换”是频率的“翻译器”,可将声音、图像等复杂信号转换为频率语言,是科学和工程领域一种基础且应用广泛的计算方式。北京大学研究团队创出一种全新的多物理域融合计算架构,可利用后摩尔新器件支持傅里叶变换,使算力提升近4倍,为具身智能、边缘感知、类脑计算、通信系统等领域开辟新的可能。该成果9日发表于《自然-电子学》。(新华社)

35分钟前

美国联邦通信委员会批准SpaceX再部署7500颗星链卫星

当地时间1月9日,美国联邦通信委员会(FCC)向SpaceX授予重大授权。根据该授权,SpaceX获准建造、部署并运营额外7,500颗第二代星链卫星,使全球卫星总数达到15,000颗。(界面新闻)

35分钟前

本页详细列出关于雷氏的品牌信息,含品牌所属公司介绍,雷氏所处行业的品牌地位及优势。
咨询